COMMUNIQUÉS West-GlobeNewswire

Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024

25/04/2024 - 14:00

BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological [...]

BioStem Technologies to Present at the 2024 Planet MicroCap Showcase

25/04/2024 - 14:00

BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024 at 11.30 am PST POMPANO BEACH, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine [...]

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

25/04/2024 - 13:30

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF [...]

Kura Oncology to Report First Quarter 2024 Financial Results

25/04/2024 - 13:30

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]

Jushi Holdings Inc. to Report First Quarter 2024 Financial Results on May 9, 2024

25/04/2024 - 13:30

BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]

Streamline Health® Signs Second Enterprise Client

25/04/2024 - 13:30

700-Bed health system adds eValuator ™ , becomes second healthcare provider leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta, GA, April 25, 2024 (GLOBE NEWSWIRE) -- Streamline Health [...]

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

25/04/2024 - 13:01

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for [...]

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

25/04/2024 - 13:00

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the [...]

Sweetwater Brewing Unveils Modern Rebrand

25/04/2024 - 13:00

The Brewery’s New Look Marks a New Era for the Craft Beer Brand ATLANTA, April 25, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast [...]

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

25/04/2024 - 13:00

Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, [...]

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25/04/2024 - 13:00

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and [...]

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

25/04/2024 - 13:00

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts John Davis brings direct clinical expertise as Nucleome advances [...]

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

25/04/2024 - 13:00

Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million [...]

Microbix Collaborator Introduces New Lab Accreditation Program

25/04/2024 - 13:00

Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life [...]

TELA Bio to Announce First Quarter 2024 Financial Results

25/04/2024 - 13:00

MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

25/04/2024 - 13:00

- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 [...]

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

25/04/2024 - 13:00

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]

Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients

25/04/2024 - 12:59

DURHAM, N.C. and DENVER, April 25, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and [...]

Nexstim Plc: Managers’ Transactions, Hildén

25/04/2024 - 12:15

Company Announcement, Helsinki, 25 April 2024 at 1:15 PM (EEST) Nexstim Plc: Managers’ Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to [...]